![]() |
Trials |
A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted TreatmentCancer type: Renal cancer Phase: II Principal Investigator: Hervonen Petteri Country: FI Keywords: Finland, Helsinki Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03173560 |